Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

81.23 +0.75 (+0.93%)
Streaming Delayed Price Updated: 2:05 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable. ↗
Investors should take note of NASDAQ:HALO, a growth stock that remains attractively priced. 
Via Chartmill
News headline image
For those who appreciate value investing, NASDAQ:HALO is a compelling option with its solid fundamentals. ↗
In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
News headline image
NASDAQ:HALO is showing good growth, while it is not too expensive. ↗
Despite its growth, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) remains within the realm of affordability. 
Via Chartmill
News headline image
NASDAQ:HALO: a strong growth stock preparing for the next leg up?. ↗
Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
News headline image
NASDAQ:HALO, an undervalued stock with good fundamentals. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) appears to be flying under the radar despite its strong fundamentals. 
Via Chartmill
News headline image
7 Underappreciated Biotech Stocks to Pick Up on the Cheap ↗
With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor. 
Via InvestorPlace
Topics Economy
News headline image
Earnings Scheduled For November 6, 2023 ↗
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
Via Benzinga
News headline image
Earnings Outlook For Halozyme Therapeutics ↗
 
Via Benzinga
News headline image
Despite its growth, NASDAQ:HALO remains within the realm of affordability. ↗
NASDAQ:HALO, a growth stock which is not overvalued. 
Via Chartmill
News headline image
NASDAQ:HALO is showing decent growth, but is still valued reasonably. ↗
Investors seeking growth at a reasonable cost should explore HALOZYME THERAPEUTICS INC (NASDAQ:HALO). 
Via Chartmill
News headline image
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures ↗
Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments. 
Via InvestorPlace
News headline image
3 Promising Biotech Stocks Flying Under the Radar ↗
Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks. 
Via InvestorPlace
News headline image
Millionaire Secrets: 3 Stocks to Turn $1,000 Into a Fortune ↗
Are you looking to invest in the stock market and become a millionaire? Here are three stocks to buy to turn $1,000 into a fortune. 
Via InvestorPlace
News headline image
For those who appreciate value investing, NASDAQ:HALO is a compelling option with its solid fundamentals. ↗
In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
News headline image
Opdivo's Subcutaneous Formulation Shows Promise in Advanced Kidney Cancer: Bristol Myers Squibb's Latest Findings ↗
Bristol Myers Squibb Co (NYSE: BMY) released topline data from the Phase 3 CheckMate -67T noninferiority trial of a subcutaneous Opdivo (nivolumab) compared to intravenous (IV) Opdivo for advanced or... 
Via Benzinga
News headline image
Analyst Expectations for Halozyme Therapeutics's Future ↗
 
Via Benzinga
News headline image
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), a strong growth stock, setting up for a breakout. 
Via Chartmill
News headline image
Where Halozyme Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Why NASDAQ:HALO Is a Standout High-Growth Stock in a Consolidation Phase. ↗
Exploring the Growth Potential of HALOZYME THERAPEUTICS INC (NASDAQ:HALO) as It Nears a Breakout. 
Via Chartmill
News headline image
NASDAQ:HALO—Positioned as a High-Growth Stock, Ready for a Potential Breakout. ↗
Is HALOZYME THERAPEUTICS INC (NASDAQ:HALO) on the Verge of a Major Breakout as a Strong Growth Stock? 
Via Chartmill
News headline image
While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is showing decent growth, but is still valued reasonably. 
Via Chartmill
News headline image
7 Sleeper Stocks That Should Be on Every Investor’s Radar This Fall ↗
Discover the thrill of undervalued and overlooked sleeper stocks poised for growth in a shifting market environment. 
Via InvestorPlace
News headline image
Expert Ratings for Halozyme Therapeutics ↗
 
Via Benzinga
News headline image
Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations ↗
Cancer drug manufacturers, including Johnson & Johnson (NYSE: JNJ), anticipate that injectable versions of some popular treatments will not be included in U.S. 
Via Benzinga
News headline image
Halozyme's Subcutaneous Drug Delivery: Analysts Initiate With 'Buy' Rating, Say Enhanze Tech Targets $41.7B Market ↗
HC Wainwright has initiated coverage on Halozyme Therapeutics Inc (NASDAQ: HALO) with a Buy rating and a  
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023 ↗
 
Via Benzinga
News headline image
Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion ↗
Roche Holdings AG's (OTC: RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with... 
Via Benzinga
News headline image
Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis ↗
The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), an injection for subcutaneous (SC) use for generalized myasthenia gravis (gMG) in adult... 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
AI Frenzy Helps Nasdaq 100 Outshine Russell 2,000 And Soar To Dot-Com Bubble Highs ↗
The surge of artificial intelligence (AI) is sparking a transformative shift in the relative valuations of prominent U.S. stock averages as the tech sector outperforms other industries and small-cap... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.